Stock comparison
Collegium Pharmaceutical
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COLL
Collegium Pharmaceutical
Market cap
$1.11B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COLL | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 65C | GMAB |
| Benjamin Graham | 62D | 64C | GMAB |
| Philip Fisher | 40D | 48D | GMAB |
| Peter Lynch | 53D | 25F | COLL |
| Joel Greenblatt | 28F | 76B | GMAB |
| Charlie Munger | 44D | 68C | GMAB |
| Terry Smith | 43D | 71C | GMAB |
Side-by-side metrics
| Metric | COLL | GMAB |
|---|---|---|
| Market cap | $1.11B | $16.5B |
| P/E (TTM) | 15.5x | 6.2x |
| EV/EBIT | 9.1x | 12.0x |
| ROIC (TTM) | 10.51% | 43.78% |
| Gross margin | 60.68% | 93.88% |
| Net margin | 9.41% | 18.23% |
| Revenue CAGR 5y | 29.58% | -18.45% |
| EPS CAGR 5y | -0.86% | -23.48% |
| Debt / Equity | 2.6x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COLL leads on
- Revenue CAGR 5y29.58%vs -18.45%+162%
- EPS CAGR 5y-0.86%vs -23.48%+96%
- EV/EBIT9.1xvs 12.0x+24%
GMAB leads on
- Debt / Equity0.1xvs 2.6x+97%
- Market cap$16.5Bvs $1.11B+93%
- ROIC (TTM)43.78%vs 10.51%+76%
- P/E (TTM)6.2xvs 15.5x+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.